Imagine being told you have a relentless form of cancer, and despite exhausting every available treatment, the disease keeps coming back. This was the grim reality for JC Cox, a retired HVAC technician from Dallas, who was diagnosed with follicular lymphoma in 2006. But what if a single, experimental treatment could turn the tide? That’s exactly what happened to JC, thanks to a groundbreaking clinical trial at MD Anderson Cancer Center. Here’s his remarkable story—and the part most people miss: it’s not just about his survival, but how his journey paved the way for a therapy that could revolutionize cancer treatment.
JC’s battle with cancer began with rounds of aggressive chemotherapy and an autologous stem cell transplant, but the follicular lymphoma persisted. By 2017, the cancer had transformed into a more aggressive form, large B-cell lymphoma, leaving him with few options. Tumors on his face and temples reappeared every two weeks after chemo, and time was running out. But here’s where it gets controversial: JC became one of the first patients to receive an experimental treatment called CAR NK cell therapy, a cutting-edge immunotherapy available only at MD Anderson at the time. This therapy uses natural killer (NK) cells, enhanced with chimeric antigen receptors (CARs), to make cancer cells visible to the immune system, allowing them to be targeted and destroyed.
Led by Dr. Katy Rezvani, a stem cell transplant and cell therapy specialist, the clinical trial offered JC a glimmer of hope. He was only the eighth person to receive this treatment, but the results were nothing short of miraculous. After a single infusion of CAR NK cells in April 2018, his scans just one month later showed no evidence of cancer. And this is the part most people miss: not only did the treatment work quickly, but it has kept JC cancer-free for seven years and counting. “I thought I was a goner,” JC admits. “But every day, it gets a little better.”
What makes CAR NK cell therapy so remarkable is its potential to offer long-lasting benefits with minimal side effects. Unlike traditional treatments, JC experienced only a slight fever after the infusion. “I felt so good, I was embarrassed to walk the halls at MD Anderson,” he recalls. While he later underwent an allogeneic stem cell transplant as a precaution, JC credits CAR NK therapy for his survival. Today, he enjoys fishing, traveling, and spending time with his family, including 11 grandchildren and five great-grandchildren.
JC’s story isn’t just about his triumph over cancer—it’s about the broader impact of his participation in the trial. When Dr. Elizabeth Shpall administered the CAR NK cells, she told him, “If this works, it’s going to help millions of people.” JC’s success played a pivotal role in the launch of MD Anderson’s Institute for Cell Therapy Discovery & Innovation in November 2024, a development that will benefit countless patients in the future. “I’m just a country boy,” JC says humbly. “But there’s no way to say enough good things about MD Anderson. They saved my life.”
But here’s the controversial question: As CAR NK cell therapy continues to evolve, will it become accessible to all who need it, or will it remain a privilege for those at select institutions? And how can we ensure that more patients like JC have the chance to participate in life-changing clinical trials? Share your thoughts in the comments—let’s keep the conversation going.
